Cytokinetics Inc CYTK:NASDAQ

Last Price$30.30NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/21/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$26.95 (2)
Ask (Size)$33.56 (2)
Day Low / HighN/A - N/A
Volume1.5 M

View Biotechnology IndustryPeer Comparison as of 01/21/2022


Cytokinetics Inc ( NASDAQ )

Price: $30.30
Change: -0.51 (1.66%)
Volume: 1.5 M
4:00PM ET 1/21/2022

Emergent BioSolutions Inc ( NYSE )

Price: $46.97
Change: +0.45 (0.97%)
Volume: 642.3 K
7:00PM ET 1/21/2022

Amicus Therapeutics Inc ( NASDAQ )

Price: $8.99
Change: -0.22 (2.39%)
Volume: 3.0 M
4:00PM ET 1/21/2022

BioCryst Pharmaceuticals Inc ( NASDAQ )

Price: $13.78
Change: -0.20 (1.43%)
Volume: 4.5 M
4:00PM ET 1/21/2022

Insmed Inc ( NASDAQ )

Price: $22.00
Change: +0.06 (0.27%)
Volume: 1.8 M
4:00PM ET 1/21/2022

Read more news Recent News

Sector Update: Health Care Stocks Slumping Near Friday Close
4:00PM ET 1/07/2022 MT Newswires

Health care stocks turned narrowly lower this afternoon, with the NYSE Health Care Index slipping 0.2% and the SPDR Health Care Select Sector ETF (XLV)...

Sector Update: Health Care Stocks Nearing Break-Even Mark Following Afternoon Uptick
1:52PM ET 1/07/2022 MT Newswires

Health care stocks have turned narrowly mixed this afternoon, with the NYSE Health Care Index rising less than 0.1% while the SPDR Health Care Select...

Sector Update: Health Care Stocks Retreat Premarket Friday
9:16AM ET 1/07/2022 MT Newswires

Health care stocks were retreating premarket Friday. The iShares NASDAQ Biotechnology Index (IBB) was 0.24% lower while the Health Care SPDR (XLV) was...

Cytokinetics Secures Up to $450 Million in Funding From Royalty Pharma for Heart Disease Drug Candidates
8:22AM ET 1/07/2022 MT Newswires

Cytokinetics (CYTK) said Friday it has secured funding of up to $450 million from Royalty Pharma (RPRX) for the potential commercialization of omecamtiv...

Company Profile

Business DescriptionCytokinetics, Inc. operates as a biopharmaceutical company. The firm focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA. View company web site for more details
Address280 East Grand Avenue
South San Francisco, California 94080
Number of Employees130
Recent SEC Filing01/07/20228-K
President, Chief Executive Officer & DirectorRobert I. Blum
Vice President-Development OperationsEric Terhaerdt
Chief Financial Officer & Senior Vice PresidentChing W. Jaw
Executive Vice President-Research & DevelopmentFady Ibraham Malik

Company Highlights

Price Open$30.52
Previous Close$30.81
52 Week Range$17.72 - 47.90
Market Capitalization$2.5 B
Shares Outstanding83.9 M
SectorHealth Technology
Next Earnings Announcement02/24/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$3.08
Beta vs. S&P 500N/A
Revenue$31.5 M
Net Profit Margin-1,061.13%
Return on Equity-204.75%

Analyst Ratings as of 01/06/2022

Consensus RecommendationConsensus Icon
Powered by Factset